Oatly Group AB - ADR vs SELLAS Life Sciences Group Inc. Common Stock — how do they compare? Oatly Group AB - ADR trades at $10.59 (market cap $330.93M), while SELLAS Life Sciences Group Inc. Common Stock trades at $11.78 (market cap $2.27B). The key difference: SELLAS Life Sciences Group Inc. Common Stock is far larger — about 6.9× Oatly Group AB - ADR's market cap, and SELLAS Life Sciences Group Inc. Common Stock is trading nearer its 52-week high, Oatly Group AB - ADR nearer its low. Which is the better fit depends on your goals.
| OTLY | SLS | |
|---|---|---|
Market Cap | $330.93M | $2.27B |
Volume | 68,708 | 4,179,659 |
Sector | Consumer Staples | Health |
52-Week High | $15.91 | $15.46 |
52-Week Low | $8.03 | $1.39 |
Typical Hold Time | 18 Days | — |
Enterprise Value | $835.34M | $2.14B |
Signals from Pluang's Aura AI — not financial advice
Oatly (OTLY) trades at $10.42, up 0.48% on the day, amid mixed technical signals and ongoing fundamental challenges. The stock shows a bearish moving average trend but bullish oscillators, with key support at $10. Revenue growth is steady, reaching $862.46M in 2025, yet profitability remains elusive with a net income margin of -13.81%. Recent Q2 2026 results beat expectations, and management raised full-year revenue guidance, driving positive sentiment from some analysts.
The outlook is cautiously optimistic, with a consensus price target of $12.28 suggesting 18% upside, but significant risks persist. High debt levels, negative cash flows, and intense competition in the plant-based food sector threaten near-term stability. Investors should weigh the potential for operational turnaround against persistent losses and leverage concerns before considering a position.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Oatly Group AB is engaged in the food and drinks industry. Some of its products include Oat Drink, Chilled Oat Drink, Oatgurt, Creamy Oat, Icecreams, among others. It caters to Sweden, Germany, United Kingdom, Netherlands, North America, Finland, and other markets.
Read more on OTLY →SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing therapies for cancer. Its programs include a WT1-targeting cancer immunotherapy and a selective CDK9 inhibitor.
Read more on SLS →